Alefacept: profile and news

Alnylam Appoints Dr. Akshay Vaishnaw as Vice President, Clinical ... Feb 7, 2006
...years he was there he was involved in many aspects of clinical research and business development, and led the effort for the approval of alefacept (Amevive(TM ... - Genetic Engineering News,

Inflammatory Diseases - Both Chronic Diseases, Such as Rheumatoid ... Feb 1, 2006
...from drugs that offer alternative approaches to the treatment of inflammatory disease, including the T-cell modulators efalizumab and alefacept and the ... - Genetic Engineering News,

Other information

Indication
For treatment of moderate to severe chronic plaque psoriasis

Pharmacology
Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.

Mechanism Of Action
Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.

Drug Category
Immunomodulatory Agents; Immunosuppresants; misc. skin and mucous membrane agents (84:92.00)

Brand Names/Synonyms
Amevive; Amevive (Biogen Inc.)

Dosage Forms
POWDER FOR SOLUTION

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Human LFA-3/IgG1 fusion protein

Chemical Formula
C2306H3594N610O694S26

Half Life
~270 hours

Drug Type
Approved Drug

# Accession No
BIOD00055

CAS Registry Number
222535-22-0